Jose Martinez-Raga

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3763286/publications.pdf

Version: 2024-02-01

87 papers 37,603 citations

30 h-index 71 g-index

102 all docs

102 docs citations

102 times ranked

63388 citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578
2	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
3	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
4	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
5	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
6	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	13.7	2,005
7	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	13.7	1,879
8	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
9	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	13.7	1,589
10	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 389, 1885-1906.	13.7	1,281
11	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
12	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
13	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573
14	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	13.7	571
15	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
16	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.7	461
17	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
18	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	13.7	284

#	Article	IF	CITATIONS
19	One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. Drug and Alcohol Dependence, 2007, 86, 91-94.	3.2	228
20	Nonmedical use of prescription drugs in the European Union. BMC Psychiatry, 2016, 16, 274.	2.6	137
21	La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. Medicina ClÃnica, 2018, 151, 171-190.	0.6	113
22	Gender differences in cocaine dependent patients: a 6 month follow-up study. Drug and Alcohol Dependence, 1997, 44, 35-40.	3.2	110
23	Risk of Serious Cardiovascular Problems with Medications for Attention-Deficit Hyperactivity Disorder. CNS Drugs, 2013, 27, 15-30.	5.9	109
24	UNPLANNED VERSUS PLANNED DISCHARGES FROM IN-PATIENT ALCOHOL DETOXIFICATION: RETROSPECTIVE ANALYSIS OF 470 FIRST-EPISODE ADMISSIONS. Alcohol and Alcoholism, 2002, 37, 277-281.	1.6	66
25	Modafinil: A Useful Medication for Cocaine Addiction? Review of the Evidence from Neuropharmacological, Experimental and Clinical Studies. Current Drug Abuse Reviews, 2008, 1, 213-221.	3.4	47
26	Add-on gabapentin in the treatment of opiate withdrawal. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 599-601.	4.8	46
27	The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 25-37.	2.3	43
28	Attention-deficit hyperactivity disorder (ADHD), substance use disorders, and criminality: a difficult problem with complex solutions. International Journal of Adolescent Medicine and Health, 2015, 27, 163-175.	1.3	41
29	Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders. European Addiction Research, 2007, 13, 230-243.	2.4	35
30	Rethinking Dual Disorders/Pathology. Addictive Disorders and Their Treatment, 2013, 12, 1-10.	0.5	34
31	1st International Experts' Meeting on Agitation: Conclusions Regarding the Current and Ideal Management Paradigm of Agitation. Frontiers in Psychiatry, 2018, 9, 54.	2.6	32
32	Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry, 2018, 18, 40.	2.6	32
33	Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition. International Journal of Adolescent Medicine and Health, 2013, 25, 231-243.	1.3	28
34	Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addiction Biology, 2003, 8, 13-21.	2.6	27
35	Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. Therapeutic Advances in Drug Safety, 2017, 8, 87-99.	2.4	27
36	What Makes Alcohol-Dependent Individuals Early in Abstinence Crave for Alcohol: Exposure to the Drink, Images of Drinking, or Remembrance of Drinks Past?. Alcoholism: Clinical and Experimental Research, 1998, 22, 1376-1381.	2.4	25

#	Article	IF	CITATIONS
37	Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. European Journal of Gastroenterology and Hepatology, 2017, 29, 629-633.	1.6	25
38	The role of personality disorders on drug dependence treatment outcomes following inpatient detoxification. European Psychiatry, 2004, 19, 187-192.	0.2	23
39	Empirical examination of executive functioning, ADHD associated behaviors, and functional impairments in adults with persistent ADHD, remittent ADHD, and without ADHD. BMC Psychiatry, 2020, 20, 134.	2.6	22
40	Who says this is a modern disorder? The early history of attention deficit hyperactivity disorder. World Journal of Psychiatry, 2015, 5, 379.	2.7	18
41	Validation of the Spanish version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Psicothema, 2014, 26, 180-5.	0.9	18
42	Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - Real World Outcomes, 2020, 7, 75-83.	1.6	16
43	Suboxone \hat{A}^{\otimes} (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis. European Addiction Research, 2010, 16, 31-42.	2.4	15
44	Dual Diagnosis Resource Needs in Spain: A National Survey of Professionals. Journal of Dual Diagnosis, 2014, 10, 84-90.	1.2	15
45	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	3.0	15
46	The Significance of a Coexisting Opioid Use Disorder in Cocaine Dependence: An Empirical Study. American Journal of Drug and Alcohol Abuse, 1996, 22, 173-184.	2.1	13
47	Does Anyone Care about Names? How Attendees at Substance Misuse Services Like to Be Addressed by Health Professionals. European Addiction Research, 2004, 10, 75-79.	2.4	13
48	Hepatitis B and C in alcohol-dependent patients admitted to a UK alcohol inpatient treatment unit. Addiction Biology, 2001, 6, 363-372.	2.6	12
49	Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment, 2015, 11, 1359.	2.2	11
50	State of Training, Clinical Services, and Research on Dual Disorders Across France, India, Israel, and Spain. Journal of Dual Diagnosis, 2016, 12, 252-260.	1.2	11
51	Addressing Dual Diagnosis Patients Suffering from Attention-Deficit Hyperactivity Disorders and Comorbid Substance Use Disorders. Addictive Disorders and Their Treatment, 2013, 12, 213-230.	0.5	10
52	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 47-61.	2.3	9
53	Hepatitis C Crónica y usuarios con un historial de inyección de drogas en España: evaluación de la población, retos para un tratamiento efectivo Revista De Psicologia De La Salud, 2017, 29, 71.	0.5	9
54	Impact of family history of alcoholism on cocaine-induced subjective effects and pharmacokinetic profile. Psychopharmacology, 2000, 152, 268-274.	3.1	8

#	Article	IF	CITATIONS
55	Los trastornos relacionados con el uso desustancias desde la perspectiva de lapsicopatologÃa y las neurociencias. Trastornos Adictivos, 2001, 3, 164-171.	0.1	8
56	Anorgasmia in a Patient Treated With Bupropion SR for Smoking Cessation. Journal of Clinical Psychopharmacology, 2004, 24, 460-461.	1.4	7
57	Developmental outcomes in adolescence of children with autism spectrum disorder without intellectual disability: A systematic review of prospective studies. Neuroscience and Biobehavioral Reviews, 2021, 126, 590-603.	6.1	7
58	Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone $\hat{A}^{@}$) in Spain. Health Economics Review, 2012, 2, 3.	2.0	5
59	Professionals' perceptions about healthcare resources for co-occuring disorders in Spain. International Journal of Mental Health Systems, 2014, 8, 35.	2.7	5
60	Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus. Dementia and Geriatric Cognitive Disorders, 2020, 49, 573-582.	1.5	5
61	Clinical guideline for the treatment of dual pathology in the adult population. Revista De Psicologia De La Salud, 2016, 28, 3.	0.5	5
62	Personalidades impulsivas y trastornos por uso de sustancias: algo más que un diagnósticodual. Trastornos Adictivos, 2002, 4, 216-222.	0.1	4
63	Subgroups of Children with Autism Spectrum Disorder without Intellectual Disability: A Longitudinal Examination of Executive and Socio-Adaptive Behaviors in Adolescence. Journal of Clinical Medicine, 2021, 10, 2220.	2.4	3
64	Homosexual Delusional Jealousy in Two Heterosexual Women. Psychopathology, 2003, 36, 33-36.	1.5	2
65	Atención y craving o ganas compulsivas. Avances en su conceptualización y su implicación en la prevención de recaÃdas. Revista De Psicologia De La Salud, 2004, 20, 365.	0.5	2
66	Positive or negative history of childhood sexual abuse among problem drinkers: relationship to substance use disorders and psychiatric co-morbidity. Journal of Substance Use, 2002, 7, 34-40.	0.7	1
67	Extrahepatic effects of alcohol: an overview. , 2002, , 467-485.		1
68	A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 965-976.	2.2	1
69	Subjective and behavioral responses and event related potentials following cocaine administration in subjects with and without a family history of alcoholism. European Psychiatry, 1996, 11, 299s.	0.2	0
70	Personality disorders in a sample of Spanish drug dependent patients admitted for inpatient detoxification. European Psychiatry, 1996, 11, 321s-322s.	0.2	0
71	Psychiatric comorbidity among opiate dependent patients in a methadone maintenance program. European Psychiatry, $1996, 11, 331s-332s$.	0.2	0
72	Use of gabapentin in the treatment of opiate withdrawal. A case series. European Neuropsychopharmacology, 2002, 12, 394.	0.7	0

#	Article	IF	CITATIONS
73	Interest in smoking cessation in a sample of Spanish alcohol and drug dependent patients. European Neuropsychopharmacology, 2002, 12, 399.	0.7	0
74	Alcohol consumption in secondary-school students: effects on plasma total antioxidant capacity. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
75	Influence of fruit intake and antioxidants on the prevention of opacities of the lens. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
76	Gluten as a precipitating factor of autoimmune diseases other than celiac disease. Proceedings of the Nutrition Society, $2010, 69, .$	1.0	0
77	PMH16 Budgetary Impact Analysis of Buprenorphine/Naloxone (Suboxone®) in Opioid Maintenance Treatment in Spain. Value in Health, 2011, 14, A289.	0.3	0
78	Consumo adictivo de sustancias psicoactivas. Medicine, 2011, 10, 5800-5809.	0.0	0
79	A Review of "Encounter Groups for Addictions: The Therapeutic Community Training Series― Journal of Groups in Addiction and Recovery, 2011, 6, 338-338.	0.4	0
80	The Role of Education on Dual Disorders: A Discussion Paper. Addictive Disorders and Their Treatment, 2017, 16, 155-163.	0.5	0
81	Structure and Functioning of Acute Inpatient Psychiatric Units in Spain: Qualitative Study. JMIR Research Protocols, 2021, 10, e26214.	1.0	0
82	Complicaciones fÃsicas del consumo de drogas recreativas. Revista De Psicologia De La Salud, 2003, 15, 207.	0.5	0
83	Nutritional Education of Secondary Education Students and Diet Quality. , 2013, , 207-218.		0
84	13. Attention-deficit hyperactivity disorder and dual disorders: educational needs for an underdiagnosed condition., 2013,, 151-172.		0
85	Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. OncoTargets and Therapy, 0, , 1359.	2.0	0
86	Relevant Differences in Perception and Knowledge of Professionals in Different Spanish Autonomous Communities Regarding Availability of Resources for Patients with Dual disorders. Actas Espanolas De Psiquiatria, 2016, 44, 1-12.	0.1	0
87	News and Notes: 2. Addiction, 2003, 98, 862-863.	3.3	O